Posts by: Marisa Wexler, MS

Marisa Wexler, MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

February 6, 2020February 6, 2020

Specific Mutations in LTA Gene Determine Risk of Ankylosing Spondylitis, Study Suggests

News

Variations in the LTA gene can alter a person’s risk of developing ankylosing spondylitis (AS), a new study suggests. The study, “Associations of lymphotoxin-a (LTA) rs909253 A/G gene polymorphism, plasma level ... Read more

January 20, 2020January 20, 2020

Health Canada Approves Cimzia for Non-radiographic Axial Spondyloarthritis

News

Health Canada has approved Cimzia (certolizumab pegol) for the treatment of adults with severe active non-radiographic axial spondyloarthritis (nr-axSpA). The medication is used to treat nr-axSpA patients with evidence ... Read more

January 9, 2020January 9, 2020

Mabpharm Seeks Approval of Infliximab Biobetter in China

News

Mabpharm has filed an application with China’s National Medical Products Administration (NMPA) seeking approval of a biobetter of infliximab, a biological treatment for people with ankylosing spondylitis and other inflammatory ... Read more

December 19, 2019December 19, 2019

Inflammation May Lead to Underestimating Efficacy of TNF Inhibitors, Study Suggests

News

The efficacy of TNF inhibitors in slowing disease progression in people with ankylosing spondylitis (AS) may be underestimated due to inflammation when treatment is started, new research suggests. The ... Read more

December 16, 2019December 16, 2019

AS Patients on Taltz Treatment Experienced Less Fatigue and Pain, and Better Sleep Over 1 Year, Phase 3 Trials Show

News

Treatment with Taltz (ixekizumab) reduces fatigue and pain in people with ankylosing spondylitis (AS) for up to one year, results from two Phase 3 trials show. The data were ... Read more

November 21, 2019November 21, 2019

FDA Approves Abrilada, Biosimilar to Humira, for Adults with Ankylosing Spondylitis and Other Disorders

News

Abrilada (adalimumab-afzb), a biosimilar to Humira (adalimumab), has been approved by the U.S. Food and Drug Administration (FDA) to treat people with seven inflammatory diseases, including adults with ankylosing spondylitis. ... Read more

November 11, 2019November 11, 2019

Bimekizumab Found to be Safe and Show Sustained Efficacy for AS Treatment in Phase 2b Trial

News

Treatment with the experimental therapy bimekizumab is safe and shows sustained efficacy over 48 weeks in people with ankylosing spondylitis (AS), data from a Phase 2b trial show. In ... Read more

October 28, 2019October 28, 2019

Higher Dosage of Cosentyx for Ankylosing Spondylitis Approved in Europe

News

The European Commission has approved a label update for Cosentyx (secukinumab) that will allow healthcare providers to prescribe doses of up to 300 mg — twice what was previously ... Read more

September 26, 2019September 26, 2019

Depression More Common in People with Ankylosing Spondylitis, Analysis Shows

News

Depression is more common among people with ankylosing spondylitis (AS) than in the general population, with about a third of patients experiencing depressive symptoms, a meta-analysis reveals. The study, ... Read more

August 12, 2019August 12, 2019

Tonsillitis May Predispose People to Ankylosing Spondylitis, Study Suggests

News

People who are diagnosed with ankylosing spondylitis (AS) are more likely to have had tonsillitis than those without this disease, a study found, suggesting that tonsillitis might predispose a ... Read more

Pin It on Pinterest